Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × revumenib × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 9 Leukemia 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Leukemia, Biphenotypic, Acute 6 Recurrence 1 Colorectal Neoplasms 1 Acute Myeloid Leukemia With KMT2A Rearrangement 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡